Please enable JavaScript to continue using this application.

Compare $CATX vs $PRLD | Chartloom

Compare

$CATX vs $PRLD

Perspective Therapeutics Inc · Prelude Therapeutics Inc

CATX

Perspective Therapeutics Inc

PRLD

Prelude Therapeutics Inc

Compare $CATX vs $PRLD

Comparing Perspective Therapeutics Inc and Prelude Therapeutics Inc

CATXPerspective Therapeutics Inc

PRLDPrelude Therapeutics Inc

CATXPerspective Therapeutics Inc

Market cap

$303M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-66.9%

YTD performance

-4.7%

52W performance

-31.1%

FCF yield

-40.0%

PRLDPrelude Therapeutics Inc

Market cap

$310M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.94x

Rev growth (TTM)

—

YTD performance

42.5%

52W performance

173.9%

FCF yield

-10.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CATX

PRLD

Detailed metrics comparison

CATX

Perspective Therapeutics Inc

PRLD

Prelude Therapeutics Inc

Market Cap

CATX$303M

PRLD$310M

Enterprise Value

CATX$256M

PRLD$284M

Price

CATX$2.66

PRLD$3.89

P/E Ratio

CATXN/A

PRLDN/A

P/S Ratio

CATX741.74x

PRLD13.82x

EV/Sales

CATX627.10x

PRLD12.64x

EV/EBITDA

CATX0.00x

PRLD0.00x

P/B Ratio

CATX0.97x

PRLD2.19x

P/FCF Ratio

CATXN/A

PRLDN/A

EV/FCF

CATX-2.11x

PRLD-8.53x

PEG Ratio

CATXN/A

PRLDN/A

Forward P/E (NTM)

CATXN/A

PRLDN/A

Forward P/S (NTM)

CATXN/A

PRLD5.94x

Revenue (TTM)

CATX$409K

PRLD$22M

Revenue Growth (YoY)

CATX-66.9%

PRLDN/A

Forward Rev Growth

CATX32.5%

PRLD-14.3%

Gross Margin (TTM)

CATX23.0%

PRLD0.0%

Operating Margin (TTM)

CATX0.0%

PRLD0.0%

EBITDA Margin (TTM)

CATX-29628.1%

PRLD-293.5%

Net Margin (TTM)

CATX-28468.0%

PRLD-269.7%

FCF Margin (TTM)

CATX-29657.2%

PRLD-148.3%

Net Income (TTM)

CATX$-116M

PRLD$-60M

FCF (TTM)

CATX$-121M

PRLD$-33M

EPS (TTM)

CATX-$0.97

PRLD-$0.61

ROE (TTM)

CATX-4156.0%

PRLD-7535.0%

ROA (TTM)

CATX-3413.0%

PRLD-4439.0%

ROIC (TTM)

CATX-4132.0%

PRLD-7535.0%

Cash

CATX$48M

PRLD$26M

Debt

CATX$2M

PRLD$0

Net Cash/Debt

CATX$47M

PRLD$26M

Current Ratio (TTM)

CATX6.61x

PRLD4.07x

Quick Ratio (TTM)

CATX6.49x

PRLD3.99x

Debt/Equity (TTM)

CATX0.00x

PRLD0.00x

Debt/Assets (TTM)

CATX0.0%

PRLD0.0%

Interest Coverage (TTM)

CATXN/A

PRLDN/A

Net Debt/EBITDA (TTM)

CATX0.00x

PRLD0.00x

Beta

CATX1.87

PRLD1.19

52W Performance

CATX-31.1%

PRLD173.9%

YTD Performance

CATX-4.7%

PRLD42.5%

% from 52W High

CATX-56.8%

PRLD-43.0%

% from 52W Low

CATX35.7%

PRLD238.3%

Asset Turnover (TTM)

CATX0.00x

PRLD0.16x

FCF Yield (TTM)

CATX-40.0%

PRLD-10.7%

Earnings Yield (TTM)

CATX-38.4%

PRLD-19.5%

Dividend Yield (TTM)

CATXN/A

PRLDN/A

Rule of 40

CATX-29,724.1

PRLD-148.3

EV/GP/RG

CATX22.31

PRLDN/A

Ticker research

View CATX research View PRLD research

Metric	CATX Perspective Therapeutics Inc	PRLD Prelude Therapeutics Inc
Market & Valuation
Market Cap	$303M	$310M
Enterprise Value	$256M	$284M
Price	$2.66	$3.89
P/E Ratio	N/A	N/A
P/S Ratio	741.74x	13.82x
EV/Sales	627.10x	12.64x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.11x	-8.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.94x
Revenue & Growth
Revenue (TTM)	$409K	$22M
Revenue Growth (YoY)	-66.9%	N/A
Forward Rev Growth	32.5%	-14.3%
Profitability
Gross Margin (TTM)	23.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-29628.1%	-293.5%
Net Margin (TTM)	-28468.0%	-269.7%
FCF Margin (TTM)	-29657.2%	-148.3%
Net Income (TTM)	$-116M	$-60M
FCF (TTM)	$-121M	$-33M
EPS (TTM)	-$0.97	-$0.61
ROE (TTM)	-4156.0%	-7535.0%
ROA (TTM)	-3413.0%	-4439.0%
ROIC (TTM)	-4132.0%	-7535.0%
Financial Health
Cash	$48M	$26M
Debt	$2M	$0
Net Cash/Debt	$47M	$26M
Current Ratio (TTM)	6.61x	4.07x
Quick Ratio (TTM)	6.49x	3.99x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	1.19
52W Performance	-31.1%	173.9%
YTD Performance	-4.7%	42.5%
% from 52W High	-56.8%	-43.0%
% from 52W Low	35.7%	238.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.16x
FCF Yield (TTM)	-40.0%	-10.7%
Earnings Yield (TTM)	-38.4%	-19.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-29,724.1	-148.3
EV/GP/RG	22.31	N/A
Ticker research	View CATX research	View PRLD research

Valuation

P/S Ratio

PRLD

13.82x

CATX

741.74x

EV/FCF

PRLD

-8.53x

CATX

-2.11x

Growth & revenue

Revenue Growth TTM

CATX

-66.9%

Forward Revenue Growth

CATX

32.5%

PRLD

-14.3%

Profitability & performance

Gross Margin

CATX

23.0%

PRLD

0.0%

ROE

CATX

-4156.0%

PRLD

-7535.0%

FCF Yield %

PRLD

-10.7%

CATX

-40.0%

52-Week Performance

PRLD

173.9%

CATX

-31.1%

Detailed metrics comparison

CATX

Perspective Therapeutics Inc

PRLD

Prelude Therapeutics Inc

Market Cap

CATX$303M

PRLD$310M

Enterprise Value

CATX$256M

PRLD$284M

Price

CATX$2.66

PRLD$3.89

P/E Ratio

CATXN/A

PRLDN/A

P/S Ratio

CATX741.74x

PRLD13.82x

EV/Sales

CATX627.10x

PRLD12.64x

EV/EBITDA

CATX0.00x

PRLD0.00x

P/B Ratio

CATX0.97x

PRLD2.19x

P/FCF Ratio

CATXN/A

PRLDN/A

EV/FCF

CATX-2.11x

PRLD-8.53x

PEG Ratio

CATXN/A

PRLDN/A

Forward P/E (NTM)

CATXN/A

PRLDN/A

Forward P/S (NTM)

CATXN/A

PRLD5.94x

Revenue (TTM)

CATX$409K

PRLD$22M

Revenue Growth (YoY)

CATX-66.9%

PRLDN/A

Forward Rev Growth

CATX32.5%

PRLD-14.3%

Gross Margin (TTM)

CATX23.0%

PRLD0.0%

Operating Margin (TTM)

CATX0.0%

PRLD0.0%

EBITDA Margin (TTM)

CATX-29628.1%

PRLD-293.5%

Net Margin (TTM)

CATX-28468.0%

PRLD-269.7%

FCF Margin (TTM)

CATX-29657.2%

PRLD-148.3%

Net Income (TTM)

CATX$-116M

PRLD$-60M

FCF (TTM)

CATX$-121M

PRLD$-33M

EPS (TTM)

CATX-$0.97

PRLD-$0.61

ROE (TTM)

CATX-4156.0%

PRLD-7535.0%

ROA (TTM)

CATX-3413.0%

PRLD-4439.0%

ROIC (TTM)

CATX-4132.0%

PRLD-7535.0%

Cash

CATX$48M

PRLD$26M

Debt

CATX$2M

PRLD$0

Net Cash/Debt

CATX$47M

PRLD$26M

Current Ratio (TTM)

CATX6.61x

PRLD4.07x

Quick Ratio (TTM)

CATX6.49x

PRLD3.99x

Debt/Equity (TTM)

CATX0.00x

PRLD0.00x

Debt/Assets (TTM)

CATX0.0%

PRLD0.0%

Interest Coverage (TTM)

CATXN/A

PRLDN/A

Net Debt/EBITDA (TTM)

CATX0.00x

PRLD0.00x

Beta

CATX1.87

PRLD1.19

52W Performance

CATX-31.1%

PRLD173.9%

YTD Performance

CATX-4.7%

PRLD42.5%

% from 52W High

CATX-56.8%

PRLD-43.0%

% from 52W Low

CATX35.7%

PRLD238.3%

Asset Turnover (TTM)

CATX0.00x

PRLD0.16x

FCF Yield (TTM)

CATX-40.0%

PRLD-10.7%

Earnings Yield (TTM)

CATX-38.4%

PRLD-19.5%

Dividend Yield (TTM)

CATXN/A

PRLDN/A

Rule of 40

CATX-29,724.1

PRLD-148.3

EV/GP/RG

CATX22.31

PRLDN/A

Ticker research

View CATX research View PRLD research

Metric	CATX Perspective Therapeutics Inc	PRLD Prelude Therapeutics Inc
Market & Valuation
Market Cap	$303M	$310M
Enterprise Value	$256M	$284M
Price	$2.66	$3.89
P/E Ratio	N/A	N/A
P/S Ratio	741.74x	13.82x
EV/Sales	627.10x	12.64x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.11x	-8.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.94x
Revenue & Growth
Revenue (TTM)	$409K	$22M
Revenue Growth (YoY)	-66.9%	N/A
Forward Rev Growth	32.5%	-14.3%
Profitability
Gross Margin (TTM)	23.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-29628.1%	-293.5%
Net Margin (TTM)	-28468.0%	-269.7%
FCF Margin (TTM)	-29657.2%	-148.3%
Net Income (TTM)	$-116M	$-60M
FCF (TTM)	$-121M	$-33M
EPS (TTM)	-$0.97	-$0.61
ROE (TTM)	-4156.0%	-7535.0%
ROA (TTM)	-3413.0%	-4439.0%
ROIC (TTM)	-4132.0%	-7535.0%
Financial Health
Cash	$48M	$26M
Debt	$2M	$0
Net Cash/Debt	$47M	$26M
Current Ratio (TTM)	6.61x	4.07x
Quick Ratio (TTM)	6.49x	3.99x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	1.19
52W Performance	-31.1%	173.9%
YTD Performance	-4.7%	42.5%
% from 52W High	-56.8%	-43.0%
% from 52W Low	35.7%	238.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.16x
FCF Yield (TTM)	-40.0%	-10.7%
Earnings Yield (TTM)	-38.4%	-19.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-29,724.1	-148.3
EV/GP/RG	22.31	N/A
Ticker research	View CATX research	View PRLD research